AbbVie Inc.
NYSE: ABBV·North Chicago, Illinois·CIK 0001551152
- Price
- $294.55
- Base IV
- $200.99
Valuation snapshot
At $294.55, the price sits between our base case ($200.99) and bull case ($305.39).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $200.99
- 68% of the price · range $110.53–$305.39
- Price vs base case
- 47% above
- $294.55 against $200.99
- Base case · our researched forecast, 2026-11-05See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $110.53 to bull $305.39. Values per share.
Price against each value
- Bear case
- $110.53
- Price 166% above
- No growth
- …
- —
- Base case
- $200.99
- Price 47% above
What does AbbVie do?
AbbVie makes prescription drugs and injectable treatments that help people control immune conditions such as psoriasis and Crohn's disease, blood and ovarian cancers, migraine, spasticity, and mood disorders.
It brought in $66B of sales in the 12 months to Sep 2026.
Led by Robert A. Michael, Chairman of the Board and Chief Executive Officer since 2024. Robert A. Michael – Chairman of the Board and Chief Executive Officer (AbbVie leadership page)
- Industry
- Healthcare
- Based in
- North Chicago, Illinois
- Trades on
- NYSE as ABBV
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 16¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 26¢ of every dollar.
- Making what it sells26¢
- Research and development15¢
- Sales, marketing and admin23¢
- Everything else it takes to operate3¢
- Interest and other costs13¢
- Tax4¢
- Left as profit16¢
Who pays AbbVie, and for what?
AbbVie discovers, makes and sells prescription medicines, mainly for immune diseases such as psoriasis and Crohn's disease, brain conditions such as migraine, schizophrenia and Parkinson's, and cancer. It also sells cosmetic treatments such as Botox Cosmetic. It earns money by selling these products. About three quarters of its sales come from the United States.
In the US, nearly all of its medicines are sold to three large drug wholesalers (McKesson, Cardinal Health and Cencora), which pass them on to pharmacies and hospitals; the final bill is largely paid by insurers, employers and government health programs such as Medicare.
Skyrizi (immunology)
29%An injected medicine for psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. It is AbbVie's biggest product and is still growing quickly.
Skyrizi prefilled injection penImage: AbbVie Rinvoq (immunology)
14%A daily pill for several immune conditions, including rheumatoid arthritis, eczema and inflammatory bowel disease. AbbVie is seeking approval for more uses, such as vitiligo.
Humira (immunology)
7%AbbVie's former best-seller for immune diseases. Its sales are falling fast because cheaper copycat versions (biosimilars) now compete with it.
Neuroscience
18%Medicines for brain and nerve conditions, including Vraylar (schizophrenia, bipolar disorder, depression), Botox Therapeutic (for example, chronic migraine), the migraine pills Ubrelvy and Qulipta, and Parkinson's treatments.
Oncology
11%Cancer medicines such as Venclexta and Imbruvica (blood cancers), Elahere (ovarian cancer) and Epkinly (lymphoma).
Aesthetics
8%Cosmetic products sold to clinics, such as Botox Cosmetic and Juvederm facial fillers. Sales fell in 2025 and were roughly flat in mid-2026.
Botox Cosmetic injection vialsImage: AbbVie
Where its work physically happens, beyond headquarters:
- Barceloneta Biologics Manufacturing Campus — Barceloneta, Puerto Rico. Produces bulk drug substance and fill-finish for Humira and other biologics, making it one of AbbVie's largest single production sites underpinning its immunology franchise revenue.
- Sligo Manufacturing Campus (Ballytivnan) — Sligo, Ireland. Houses two biologics plants supplying immunology and oncology drug product to European and global markets, a key node in AbbVie's international supply chain.
- Singapore Manufacturing Facility (Tuas Biomedical Park) — Tuas, Singapore. AbbVie's only manufacturing location in Asia, producing small-molecule and biologics drug substance and undergoing a $223 million capacity expansion to support immunology and oncology pipeline products.
- Irvine Aesthetics R&D and Manufacturing Site — Irvine, United States. Global hub for Allergan Aesthetics research, development and manufacturing of Botox Cosmetic and the Juvederm filler collection, core products of AbbVie's multibillion-dollar Aesthetics segment.
- AbbVie Bioresearch Center — Worcester, United States. A center of excellence for biologics R&D and manufacturing currently undergoing a $70 million expansion to add immunology and oncology monoclonal antibody manufacturing capacity in the U.S.
How is the business doing?
Sales grew from $45.8B in 2020 to $61.2B in 2025, about 6% a year.
Running the business leaves about 32¢ of each sales dollar as operating profit, up from 25¢ in 2020.
After paying for its upkeep and new investment, it had $18.9B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
AbbVie says it exists to discover and deliver new medicines that treat serious diseases now and tackle future medical challenges.
“to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow”
Who is responsible for the plan?
- Robert A. MichaelChairman of the Board and Chief Executive Officer
Leads AbbVie as chief executive officer and chairs its Board of Directors. As CEO he is accountable for AbbVie's whole business, which earns revenue from selling prescription medicines and aesthetics products worldwide.
- Jeffrey R. StewartExecutive Vice President, Chief Commercial Officer
Oversees AbbVie's commercial organization as Chief Commercial Officer. The commercial organization markets and sells AbbVie's medicines, and those product sales are where the company's revenue comes from.
- Roopal Thakkar, M.D.Executive Vice President, Research & Development and Chief Scientific Officer
Leads AbbVie's global research and development organization as Chief Scientific Officer. R&D discovers and develops the drug candidates that AbbVie hopes to bring to market and sell as approved medicines.
Roles checked November 6, 2026.
What management says it is working on now:
Growing Skyrizi and Rinvoq
Management is relying on these two immune-disease medicines to replace lost Humira sales. In the second quarter of 2026 each grew about 24%, and together they made up nearly half of company sales. AbbVie raised its 2026 sales forecast for Skyrizi to about $21.7 billion.
AbbVie Reports Second-Quarter 2026 Financial ResultsExpanding neuroscience
Neuroscience sales rose about 20% in the second quarter of 2026 to $3.2 billion, led by Vraylar and Botox Therapeutic. AbbVie is adding new brain medicines, including its Parkinson's pill tavapadon.
AbbVie Reports Second-Quarter 2026 Financial ResultsBuying and licensing new drugs
AbbVie agreed to buy Apogee Therapeutics for about $10.9 billion to add an eczema drug candidate. It also licensed a drug from RemeGen for $650 million upfront, with up to $5.0 billion more in possible milestone payments.
AbbVie Inc. Form 10-Q for the quarter ended June 30, 2026Getting more uses approved for existing drugs
AbbVie is asking regulators to approve Rinvoq for more conditions, such as the skin-color disorder vitiligo. On the second-quarter call, management said Rinvoq's sales in vitiligo and the hair-loss condition alopecia areata could approach $2 billion a year at their peak.
AbbVie Q2 earnings call highlights (Nasdaq)
- Total net revenues, Full year 2026
- About $67.6 billion (raised twice during the year)
- AbbVie Q2 earnings call highlights (Nasdaq)
- Adjusted earnings per share, Full year 2026
- $13.87 to $14.07
- AbbVie Reports Second-Quarter 2026 Financial Results
- Skyrizi plus Rinvoq combined revenues, 2026
- More than $31 billion, beating the earlier 2027 goal of $31 billion a year early
- AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
- Rinvoq peak sales in vitiligo and alopecia areata, At peak (no year given)
- Approaching $2 billion a year
- AbbVie Q2 earnings call highlights (Nasdaq)
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 10% more than a year earlier. The year before, quarters averaged 10%.
Its operating margin is wider than a year ago: 36¢ per sales dollar, against 12¢.
Since Aug 2026 the share price has risen 17%, from $250.82 to $294.55.
Recently
September 30, 2026
Skyrizi and Rinvoq Combined Net Revenue (Quarterly) changed to $8.5B
AbbVie Q3 2026 Earnings ReleaseJune 30, 2026
Q2 GAAP operating profitability changed to 37.9%
AbbVie Q2 2026 resultsJune 30, 2026
Skyrizi and Rinvoq Q2 revenue changed to $8.0B
AbbVie Q2 2026 Form 10-Q
Coming up
Approved September 2026; launch expected October 2026
Launch of Parkinson's pill Juvmo (tavapadon)
The FDA approved tavapadon, sold as Juvmo, a once-daily pill for adults with Parkinson's disease. It came from AbbVie's purchase of Cerevel. A US launch was reported for October 2026.
US FDA approves AbbVie drug for Parkinson's disease (Khaleej Times / Reuters)Closed September 3, 2026
Apogee acquisition completed
AbbVie closed its roughly $10.9 billion purchase of Apogee, adding zumilokibart, a late-stage eczema drug candidate. AbbVie expects the deal to reduce adjusted earnings per share by about $0.14 in 2026 and $0.46 in 2027.
AbbVie Inc. Form 8-KPending; filed February 2026
US decision on Rinvoq for vitiligo
AbbVie asked the FDA in February 2026 to approve Rinvoq for non-segmental vitiligo in people aged 12 and older. A US decision is still pending. Europe has reportedly approved it.
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ in VitiligoJanuary 1, 2027
Medicare-set prices for Vraylar and Linzess
Prices that Medicare set under the Inflation Reduction Act take effect for Vraylar and Linzess, which could lower what AbbVie earns from these drugs.
AbbVie Inc. Form 10-K for fiscal year 2025, Item 1A Risk Factors
Our own estimate moved too: the base case went from $223.72 to $200.99 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Reliance on two medicines
Skyrizi and Rinvoq brought in about 42% of 2025 sales. Any new competitor, safety problem or patent challenge for either drug would hit the whole company hard. Their main US patents are expected to expire in 2033.
From the company's own filingsWould hit how fast sales growAbbVie Inc. Form 10-K for fiscal year 2025, Item 1A Risk Factors
Medicare price setting
Under a US law called the Inflation Reduction Act, Medicare sets the prices it pays for some drugs. This applies to Imbruvica from 2026, Vraylar and Linzess from 2027, and Botox from 2028, which could lower sales of these products.
From the company's own filingsWould hit how much of each sale it keepsAbbVie Inc. Form 10-K for fiscal year 2025, Item 1A Risk Factors
Cheaper copycat drugs
When patents run out, cheaper copies can take most of a drug's sales. Humira shows this: its sales fell about 36% in the second quarter of 2026. AbbVie warns the same could happen to other products, possibly earlier than it expects.
From the company's own filingsWould hit how fast sales growAbbVie Inc. Form 10-K for fiscal year 2025, Item 1A Risk Factors
Pricing pressure from insurers and middlemen
Governments, insurers and pharmacy benefit managers push for lower drug prices and can limit which drugs patients can get. Management expects small price declines for Skyrizi and Rinvoq each year over the next few years.
From the company's own filingsWould hit how much of each sale it keepsAbbVie Inc. Form 10-K for fiscal year 2025, Item 1A Risk Factors
New drugs may fail
Research is costly and many drug candidates never reach patients. AbbVie also pays large sums to buy or license drugs from other companies, such as $10.9 billion for Apogee, and those drugs may not succeed.
From the company's own filingsWould hit how much it has to reinvestAbbVie Inc. Form 10-K for fiscal year 2025, Item 1A Risk Factors
Large debt
AbbVie borrowed about $8 billion in the first half of 2026. It had about $8.3 billion of long-term debt due within a year as of June 30, 2026, which it will need to repay or refinance.
From the company's own filingsAbbVie Inc. Form 10-Q for the quarter ended June 30, 2026
Aesthetics segment revenue fell 1.4% in Q3 2026 to $1.176 billion due to persistent softening in dermal filler demand.
From our researchWould hit how fast sales growAbbVie Q3 2026 Form 10-Q
Historical full-year GAAP margins fluctuate sharply during acquisition years, dropping to negative 9.9% in Q4 2024 upon upfront IPR&D recognition.
From our researchWould hit how much of each sale it keepsAbbVie 2024 Form 10-K
Is it a good business?
From 2016 to 2025 it earned between 10% and 54% on the capital invested in it, a median of 20%. Its cost of capital in the latest valuation is 6.7%; returns were above it in every one of the 10 years.
From 2016 to 2024 it earned between 35% and 129% on its shareholders' equity, a median of 75%.
Over 10 years its operating margin ranged from 16¢ to 39¢ per sales dollar, a median of 28¢. Gross margin ran from 62¢ to 78¢.
Cost of capital 6.7%
The number of shares has held roughly steady over the past year.
It owes $70.1B more than it holds in cash, about 3.3 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $294.55. Our put its value between $110.53 and $305.39, with $200.99 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $110.53
This scenario envisions revenue expansion slowing down markedly as newer medications face stiff competition and government pricing pressure while ongoing acquisitions remain necessary to replenish the medicine pipeline.
Base case, $200.99
This scenario reflects steady mid-single-digit sales growth as blockbuster therapies capture additional market share while the business maintains healthy cash generation and disciplined reinvestment.
Bull case, $305.39
This scenario envisions robust double-digit expansion powered by outsized demand for core autoimmune and neurological treatments alongside expanding profit margins as sales scale over fixed overhead.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 47%
For AbbVie to be worth today's $294.55, sales would need to grow about 13.2% a year. We assume 5.5%. Over the last 5 years, sales grew 3.7% a year.
Or, if sales grow 5.5% as we assume, the price works with a profit margin of 48.6% (we assume 35.0%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 13.2% a year?
Try your own numbersWe're moderately sure of this range: it scores 56 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $200.99 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.5%
- Operating margin35.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$200.99 -31.8%


